DE69435261D1 - Menschlicher rezeptor h4-1bb - Google Patents

Menschlicher rezeptor h4-1bb

Info

Publication number
DE69435261D1
DE69435261D1 DE69435261T DE69435261T DE69435261D1 DE 69435261 D1 DE69435261 D1 DE 69435261D1 DE 69435261 T DE69435261 T DE 69435261T DE 69435261 T DE69435261 T DE 69435261T DE 69435261 D1 DE69435261 D1 DE 69435261D1
Authority
DE
Germany
Prior art keywords
receptor protein
human
protein
cells
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435261T
Other languages
English (en)
Inventor
Byoung S Kwon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22404839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69435261(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Application granted granted Critical
Publication of DE69435261D1 publication Critical patent/DE69435261D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69435261T 1993-09-16 1994-09-15 Menschlicher rezeptor h4-1bb Expired - Lifetime DE69435261D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12279693A 1993-09-16 1993-09-16
PCT/US1994/010457 WO1995007984A1 (en) 1993-09-16 1994-09-15 Human receptor h4-1bb

Publications (1)

Publication Number Publication Date
DE69435261D1 true DE69435261D1 (de) 2010-02-25

Family

ID=22404839

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69435261T Expired - Lifetime DE69435261D1 (de) 1993-09-16 1994-09-15 Menschlicher rezeptor h4-1bb

Country Status (11)

Country Link
US (3) US8026353B2 (de)
EP (1) EP0719329B1 (de)
JP (2) JPH09503911A (de)
KR (2) KR100244960B1 (de)
AT (1) ATE454449T1 (de)
AU (1) AU697482B2 (de)
CA (2) CA2429027C (de)
DE (1) DE69435261D1 (de)
ES (1) ES2341631T3 (de)
NZ (1) NZ273838A (de)
WO (1) WO1995007984A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
NZ273838A (en) 1993-09-16 1997-09-22 Indiana University Foundation Human receptor protein h4-1bb
DK0766745T3 (da) * 1995-04-08 2002-11-25 Lg Chemical Ltd Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
US5874240A (en) * 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
WO1997033898A1 (en) * 1996-03-15 1997-09-18 Human Genome Sciences, Inc. Human 4-1bb receptor splicing variant
AU738981B2 (en) * 1996-10-11 2001-10-04 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
CZ20003238A3 (cs) * 1998-07-15 2001-10-17 Merckle Gmbh Pouľití CD137 pro podporu proliferace periferních monocytů
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
DE60232895D1 (de) 2001-10-09 2009-08-20 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
CA2492561A1 (en) * 2002-07-15 2004-01-22 Mayo Foundation For Medical Education And Research Treatment and prophylaxis with 4-1bb-binding agents
US20060121030A1 (en) * 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20070253961A1 (en) * 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
PT1810026T (pt) 2004-10-06 2018-06-11 Mayo Found Medical Education & Res B7-h1 e pd-1 no tratamento do carcinona de células renais
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
ES2417147T3 (es) * 2005-10-21 2013-08-06 Revo Biologics, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
EP2279003A4 (de) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc Anti-cd137-antikörper als mittel zur behandlung von entzündlichen erkrankungen
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
WO2011149025A1 (ja) * 2010-05-28 2011-12-01 株式会社上野忠 経口用体温上昇剤
NZ612512A (en) * 2010-12-09 2015-03-27 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX2013008376A (es) 2011-01-18 2013-08-12 Univ Pennsylvania Composiciones y metodos para el tratamiento de cancer.
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2015050663A1 (en) 2013-10-01 2015-04-09 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of bim
IL280215B (en) 2014-04-07 2022-07-01 Novartis Ag Cancer treatment using a chimeric receptor antigen (car) against cd19
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
US10253086B2 (en) 2015-04-08 2019-04-09 Novartis Ag CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
EP3523331A1 (de) 2016-10-07 2019-08-14 Novartis AG Chimäre antigenrezeptoren zur behandlung von krebs
BR112019014991A2 (pt) 2017-01-20 2020-04-07 Magenta Therapeutics Inc composições e métodos para a supressão de células cd137+
TWI820031B (zh) 2017-07-11 2023-11-01 美商坎伯斯治療有限責任公司 結合人類cd137之促效劑抗體及其用途
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP4110826A1 (de) 2020-02-28 2023-01-04 Shanghai Henlius Biotech, Inc. Anti-cd137-konstrukte, multispezifischer antikörper und dessen verwendungen
WO2021170067A1 (zh) 2020-02-28 2021-09-02 上海复宏汉霖生物技术股份有限公司 抗cd137构建体及其用途
CN114605541B (zh) * 2021-08-26 2023-08-29 北京大学深圳研究生院 一种抗4-1bb纳米抗体、编码基因及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
US4837306A (en) * 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US7211259B1 (en) * 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7138500B1 (en) * 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
WO1994026290A1 (en) 1993-05-07 1994-11-24 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
NZ273838A (en) 1993-09-16 1997-09-22 Indiana University Foundation Human receptor protein h4-1bb
DK0766745T3 (da) 1995-04-08 2002-11-25 Lg Chemical Ltd Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette

Also Published As

Publication number Publication date
KR100271382B1 (en) 2000-11-15
AU697482B2 (en) 1998-10-08
KR100244960B1 (ko) 2000-02-15
US20020168719A1 (en) 2002-11-14
ES2341631T3 (es) 2010-06-23
US20070117161A1 (en) 2007-05-24
US8026353B2 (en) 2011-09-27
CA2429027A1 (en) 1995-03-23
US20080312418A1 (en) 2008-12-18
ATE454449T1 (de) 2010-01-15
EP0719329A1 (de) 1996-07-03
AU7729494A (en) 1995-04-03
JPH09503911A (ja) 1997-04-22
EP0719329B1 (de) 2010-01-06
NZ273838A (en) 1997-09-22
CA2172165A1 (en) 1995-03-23
CA2172165C (en) 2003-12-02
CA2429027C (en) 2011-04-05
JP2006149389A (ja) 2006-06-15
WO1995007984A1 (en) 1995-03-23

Similar Documents

Publication Publication Date Title
DE69435261D1 (de) Menschlicher rezeptor h4-1bb
Blazar et al. Recent advances in graft‐versus‐host disease (GVHD) prevention
Lane et al. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation.
Luescher et al. CD8 modulation of T-cell antigen receptor–ligand interactions on living cytotoxic T lymphocytes
US5747037A (en) Anti-GP39 antibodies
Fangmann et al. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.
Mechtersheimer et al. Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors
Bonnefoy et al. The low-affinity receptor for IgE (CD23) on B lymphocytes is spatially associated with HLA-DR antigens.
AU784634B2 (en) B7-H1, a novel immunoregulatory molecule
CA2246352A1 (en) Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
Wade et al. Structural compartmentalization of MHC class II signaling function
KR940007179A (ko) 시디40 (cd40)을 위한 수용성 리간드
US20100015153A1 (en) Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
Lanier et al. Natural killer cells
US20030044416A1 (en) Nucleic acids encoding cd100 molecules
WO1995024217A1 (en) Methods for modulating t cell unresponsiveness
US7476385B2 (en) Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1
JP2004537500A (ja) 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物
Mortara et al. Therapy‐induced antitumor vaccination by targeting tumor necrosis factor‐α to tumor vessels in combination with melphalan
EP0742721B1 (de) Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet
Rau et al. MHC-restricted and-unrestricted CD8 T cells: an evolutionary perspective
EP1240326A2 (de) Auslösende rezeptor, der am natürlichen cytotoxizität der menschlichen natürlichen killerzellen beteiligt ist, und sie identifizierende antikörper
Bromberg The biology of CD2: adhesion, transmembrane signal, and regulatory receptor of immunity
Macphail et al. L3T4+ cytotoxic T lymphocytes specific for class I H-2 antigens are activated in primary mixed lymphocyte reactions.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition